Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-1161 vs Duodart PK Study in Healthy Males (Fed)
NCT07444385Phase 1Recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dutasteride + tamsulosin hydrochloride in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve during dosing interval and Maximum concentration of drug in plasma. Started Feb 2026; status: recruiting.
02
Drugs
dutasteride + tamsulosin hydrochloride
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07444385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444385.